Zhuojun Ling
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Five-year outcome of CD19 followed by CD22 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia patients who relapsed after allo-transplantation.
Journal: Haematologica
Published: August 28, 2024
Autologous CD7 CAR-T cells generated without T cell pre-selection in pediatric patients with relapsed/refractory T-ALL: A phase I trial.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: April 16, 2024
Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial.
Journal: Nature medicine
Published: December 20, 2023
C-JUN overexpressing CAR-T cells in acute myeloid leukemia: preclinical characterization and phase I trial.
Journal: Nature communications
Published: September 13, 2023
Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.
Journal: The Lancet. Oncology
Published: February 23, 2023
Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia.
Journal: Journal of hematology & oncology
Published: January 19, 2023
Corrigendum: Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL.
Journal: Frontiers in oncology
Published: September 16, 2021
Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 29, 2021
A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL.
Journal: Blood cancer journal
Published: January 21, 2021
Last Updated: 09/26/2026